Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

Novartis AG (NVS) reports a strong quarter with significant sales increases across key products and a record $6 billion in ...

Novartis hopes Kisqali will give Pfizer’s Ibrance (palbociclib) blockbuster a run for its money in first line HR+/HER2+ metastatic breast cancer. Although Pfizer beat Novartis to market with ...

Good morning and good afternoon, and welcome to the Novartis Q3 2024 Results Release ... talk about a bit more over the course of the call; Kisqali's FDA approval and CHMP positive opinion in ...

Meanwhile, Novartis has gained two new FDA approvals in the US for its breast cancer drug Kisqali and Fabhalta which is used in the reduction of proteinuria in adults. Commenting on Q3 2024 ...

Kisqali’s (breast cancer ... up 50% on solid growth in the United States and Europe. Novartis received approval for Pluvicto's expanded manufacturing capacity at Millburn, NJ.

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...